Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amélie Mallet1, De Calbiac Ombline1, Marie Robert1

  • 1Département d'oncologie médicale, Institut de cancérologie de l'Ouest - René Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.

Bulletin Du Cancer
|December 31, 2021
PubMed
Summary

HER2-low breast cancer, previously untreatable, can now benefit from antibody-drug conjugates (ADCs). These targeted therapies show efficacy and manageable toxicity, offering new hope for patients with this subtype.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective SAJAC Study of Rehabilitation for Adolescents and Young Adults with Cancer in a Comprehensive Cancer Center.

Journal of adolescent and young adult oncology·2026
Same author

Integration of functional immunomonitoring assays with PET/CT scans in TB patients identifies on-treatment biomarkers.

bioRxiv : the preprint server for biology·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

NOXA/MCL-1 axis determines cell-death decision between apoptosis and a GSDME-dependent cell death associated with production of inflammatory cytokines upon treatment of breast cancer cells with antimitotics.

Cell death & disease·2026
Same author

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

The oncologist·2026
Same author

Not just splitting hairs-monitoring environmental chemical exposures, their biological effects and their social determinants with hair shafts and follicles: a narrative review.

Environmental health : a global access science source·2026

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2-low breast cancer represents a newly defined subtype.
  • Traditionally, these tumors were classified as luminal or triple-negative, lacking targeted therapies.
  • The human epidermal growth factor receptor 2 (HER2) is a target for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of antibody-drug conjugates (ADCs) in HER2-low breast cancer.
  • To explore the potential of HER2 as a target for drug delivery in this patient population.
  • To discuss the implications of ADCs for future therapeutic strategies in HER2-low breast cancer.

Main Methods:

  • Review of current clinical trials and development of ADCs targeting HER2.
  • Analysis of efficacy data for trastuzumab deruxtecan monotherapy and combination studies.
Keywords:
Breast cancer HER2-low Antibody drug conjugateCancer du sein HER2-low Conjugué anticorps drogue

Related Experiment Videos

  • Assessment of toxicity profiles of various ADCs in HER2-low breast cancer patients.

    • Main Results:

    • ADCs demonstrate significant clinical efficacy in HER2-low breast cancer.
    • Trastuzumab deruxtecan is under investigation in Phase III trials for HER2-low breast cancer.
    • Emerging ADCs show promising results and manageable toxicity profiles.

    Conclusions:

    • HER2-low breast cancer may benefit from dedicated therapeutic strategies.
    • ADCs offer a promising new avenue for treating HER2-low breast cancer.
    • Continued development of ADCs is anticipated to yield further advancements in patient care.